OABIW
OmniAb, Inc.
$2.57
+0.05 (+1.98%)
Institutional flow:
-1% holders QoQ · +24 funds added
Insider flow:
Net -$49.6K over 90 days · 100% sells
Short interest:
3.24% of float · ▲ +0.4% MoM · 10.0 days cover
Institution breadth:
128 holders — near 3-yr low, contrarian setup
3 Up Days
Indicators
Price
Panels
Event markers
Price & Indicators
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.57
Open$2.52
Day$2.47–2.61
52W$1.30–2.79
Avg vol 30d638K
Short int4.7M · 10.0d
Short vol57%
Last earningsMay 7, 2026
DataSep 2021–Jun 2026
Filing10-Q · May 7
Equibles Rating
blended score
Overall
Neutral
Technical · trend & momentum
Strong Buy
+
Price vs 200-day avg · +41% above
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+41% above
+
Price vs 50-day avg
+23% above
◦
RSI (14)
61 · neutral
+
MACD trend
positive
+
52-week position
85% · near high
Sentiment · smart money
Bearish
−
Institutional flow · -1% holders QoQ · +24 funds added
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
−
Institutional flow
-1% holders QoQ · +24 funds added
−
Insider flow
Net -$49.6K over 90 days · 100% sells
−
Short interest
3.24% of float · ▲ +0.4% MoM · 10.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
128 holders — near 3-yr low, contrarian setup
Fundamentals
Weak
−
Revenue growth · −29% Y/Y
−
Revenue growth
−29% Y/Y
◦
EPS growth
+7% Y/Y
−
Free cash flow
$-37.0M
+
Balance sheet
net cash $25.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Key facts
Market Cap
$372.58M
Shares
144,972,579
CIK
1846253
CUSIP
68218J103
Website
Visit website
Investor Relations
Investor relations
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
2026
Revenue
$28M – $33M
prior FY $18.67M
midpoint +63.4% Y/Y
Costs and operating expenses
$83M – $88M
end of 2026
Cash and cash equivalents
$33M – $38M
full-year 2026
Effective tax rate
at least 0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+41% above
Bullish
Price vs 50-day avg
+23% above
Bullish
RSI (14)
61 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
85% · near high
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$49.6K over 90 days · 100% sells
Short interest
Rising
3.24% of float · ▲ +0.4% MoM · 10.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
128 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $3 · 85%
52-wk high $3
vs 200-day avg +41%
vs 50-day avg +23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OABIW
this stock
OmniAb, Inc.
|
$372.58M | +38.9% | -29.3% | — | 3.2% |
|
AKTX
Akari Therapeutics Plc
|
$938.56B | -11.3% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$458.20B | -4.5% | +22179.2% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.40B | +9.8% | +46.2% | — | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$66.52B | -19.1% | +20.8% | — | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OABIW | +10.8% | -4.8% | +38.9% | -4.8% | +38.9% |
| SPY | -0.5% | -2.1% | +7.8% | -2.1% | +8.7% |
| vs SPY | +11.2% | -2.8% | +31.2% | -2.8% | +30.3% |